Following the ban on rosiglitazone in Europe and the restricted access in the United States, the Indian government has imposed a ban on the import and manufacture of the diabetes drug in the country.
People using rosiglitazone have experienced a number of serious side effects including cardiovascular events and adverse effects on lipid profile leading to its ban in Europe.
AdvertisementAn Expert Committee on October 7 recommended a similar ban in India which was enforced with immediate effect.
The Drugs Controller General of India (DCGI) Dr Surinder Singh revealed that directives have been sent to state drugs controllers in the country regarding the suspension of licenses granted to manufacture for sale and distribution of the drug.
You May Also Like